CliffBio
small molecule

SINEMET CR

CARBIDOPA; LEVODOPA

Loss of exclusivity—loss of exclusivity
CompanyOrganon →See this company's full patent-cliff portfolio

Drug detail

Brand nameSINEMET CR
Active ingredientCARBIDOPA; LEVODOPA
Strength50MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMay 1991
Marketing statusDISCN

More from Organon

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

SINEMET CR patent cliff — loss of exclusivity — | CliffBio